Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine

Trück, Johannes; Kelly, Sarah; Jawad, Sena; Snape, Matthew D.; Voysey, Merryn; Pollard, Andrew J.

doi:10.1097/inf.0000000000001894

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-four children (Table 1) who had received the 13-valent pneumococcal conjugate vaccine (PCV-13) at 12 months of age, as part of a previously published clinical trial [19][20][21], were selected based on their aggregated IgG antibody response and categorized into high and low responders ( Fig. 1 and Additional file 1: Figure 1).…”

Section: Resultsmentioning

confidence: 99%

“…In a previous clinical trial, 178 children were randomized to receive a booster dose of either the 10-or the 13-valent pneumococcal conjugate vaccine (PCV-13) at 12 months of age following receipt of PCV-13 at 2 and 4 months of age [19][20][21]. Ethical approval for this clinical vaccine trial was obtained from the Oxfordshire Research Ethics Committee (Reference number 11/SC/0473).…”

Section: Study Subjects and Sample Selectionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in epigenetic profiles throughout early childhood and their relationship to the response to pneumococcal vaccination

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Pneumococcal infections are a major cause of morbidity and mortality in young children and immaturity of the immune system partly underlies poor vaccine responses seen in the young. Emerging evidence suggests a key role for epigenetics in the maturation and regulation of the immune system in health and disease. The study aimed to investigate epigenetic changes in early life and to understand the relationship between the epigenome and antigen-specific antibody responses to pneumococcal vaccination. Methods The epigenetic profiles from 24 healthy children were analyzed at 12 months prior to a booster dose of the 13-valent pneumococcal conjugate vaccine (PCV-13), and at 24 months of age, using the Illumina Methylation 450 K assay and assessed for differences over time and between high and low vaccine responders. Results Our analysis revealed 721 significantly differentially methylated positions between 12 and 24 months (FDR < 0.01), with significant enrichment in pathways involved in the regulation of cell–cell adhesion and T cell activation. Comparing high and low vaccine responders, we identified differentially methylated CpG sites (P value < 0.01) associated with HLA-DPB1 and IL6. Conclusion These data imply that epigenetic changes that occur during early childhood may be associated with antigen-specific antibody responses to pneumococcal vaccines.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Subjects and Sample Selectionmentioning

confidence: 99%